

**Table 2.18. Case-control studies of HPV AIN prevalence**

Reference, study location	Method of detection	No. of cases	No. of controls	Sites included	HPV prevalence (%)		Odds ratio (95% CI)	Comments
					Cases	Controls		
Carter <i>et al.</i> (2001), USA	Seropositivity to HPV16 and HPV18 capsid proteins by ELISA (L1)	32 Female	1326	Sera	N=16/32 (50%) HPV16 L1 Ab	N=202/1326 (15.2%) HPV16 L1 Ab	5.7 (2.8–11.6)	Sera
					N=3/7 (42%) HPV16 L1 Ab + HPV16 DNA +	N=202/1326 (15.2%) HPV16 L1 Ab + HPV16 DNA +	4.2 (0.9–18.9)	
					N=14/32 (43.8%) HPV18 L1 Ab	N=204/1322 (15.4%) HPV18 L1 Ab	4.2 (2.1–8.6)	
					N=2/3 (66.7%) HPV18 L1 Ab + HPV18 DNA +	N=204/1322 (15.4%) HPV18 L1 Ab + HPV18 DNA +	–	
		41 Male	218	Sera	N=27/41 (65.9%) HPV16 L1 Ab	N=34/218 (15.6%) HPV16 L1 Ab	10.7 (5.0–23.0)	Sera
					N=11/15 (73.3%) HPV16 L1 Ab + HPV16 DNA +	N=34/218 (15.6%) HPV16 L1 Ab + HPV16 DNA +	16.0 (4.6–55.7)	